Skip to main content
Clinical Trials/EUCTR2017-001778-40-ES
EUCTR2017-001778-40-ES
Active, not recruiting
Phase 1

A Prospective Randomized Trial Comparing the Effect of 2 vitamin D supplementation regimens in elderly people after hip fracture surgery

eonor Cuadra Llopart0 sitesOctober 2, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hip fracture and vitamin D deficiency
Sponsor
eonor Cuadra Llopart
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 2, 2017
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
eonor Cuadra Llopart

Eligibility Criteria

Inclusion Criteria

  • Patients aged \> or \=75 years with hip fracture by fragility and vitamin D deficiency.
  • Definitions:
  • \* Fracture by fragility: understood as such those that are produced by trauma of low intensity (for example, falls from the own height in standing or smaller)
  • \* Vitamin D deficiency: 25\-OH\-D3 serum levels \<30 ng / mL
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 50

Exclusion Criteria

  • \* Presence of severe functional dependence prior to fracture of the femur (I. Barthel \<35 points)
  • \* Diagnosis of dementia to a moderate degree (defined on the Reisberg scale as GDS\-FAST\> 5\).
  • \* Medical conditions that contraindicate receiving vitamin D supplementation
  • \- hypercalcemia (calcemia\> 10\.5 mg / dL),
  • \- hyperparathyroidism
  • \- chronic renal failure with GFR \<30 mL / min,
  • \- calcium lithiasis
  • \- pathologies with risk of hypercalcemia (tuberculosis, sarcoidosis ...), as well as pathologies involving intestinal malabsorption.
  • \- Hypersensitivity to the active substance or to any of the excipients.
  • \* Use of drugs that interact with the use of vitamin D and with the risk of causing hypercalcemia (phenytoin, phenobarbital, primidone, digoxin).

Outcomes

Primary Outcomes

Not specified

Similar Trials